top of page
1/2
Pioneering Novel
Life-Saving Medicines
for Cardiomyopathies
Our Mission
At Nuevocor, our mission is to transform the treatment of untreatable cardiomyopathies by embracing a mechanobiology-centered approach.
These devastating conditions pose a significant global healthcare challenge, affecting individuals at a relatively young age and can rapidly lead to heart failure. Presently, the only recourse for these patients is a costly and often elusive cardiac transplant.
To address this challenge, we are building global collaborations with leading experts and institutions, accelerating the development of innovative solutions that offer these patients viable alternatives and improved outcomes.
About Us
With global operations across the United States, Europe and Singapore, Nuevocor focuses on treating heart conditions known as cardiomyopathies by addressing their underlying mechanical defects.
Nuevocor’s lead program, NVC-001, is a novel genetic medicine that treats patients suffering from LMNA-related dilated cardiomyopathy, an aggressive, rare disease with no available targeted treatments.
News
7 January 2026
Nuevocor Appoints Al Gianchetti as Chief Executive Officer
SINGAPORE & PARIS & PHILADELPHIA--(BUSINESS WIRE)--Nuevocor, a global biotechnology company, today announced the appointment of Al Gianchetti as Chief Executive Officer (CEO) and member of the Board of Directors. Nuevocor develops novel therapies for patients suffering from life-threatening cardiomyopathies, who currently have no effective treatments. Nuevocor’s science addresses the underlying aberrant mechanobiology that drives the progress of disease.
7 July 2025
Nuevocor Strengthens Board with Appointment of Thierry Abribat
SINGAPORE, July 7, 2025 /PRNewswire/ -- Nuevocor, a Singapore-headquartered biotechnology company developing cures for cardiomyopathies driven by aberrant mechanobiology, today announced the appointment of Dr. Thierry Abribat to its Board of Directors.
bottom of page